23andMe Personal Genome Service (PGS) Genetic Health Risk Report Package Insert BRCA1/BRCA2 (Selected Variants)
|
|
- Joshua Lester
- 6 years ago
- Views:
Transcription
1 23andMe Personal Genome Service (PGS) Genetic Health Risk Report Package Insert /BRCA2 (Selected Variants) Table of contents Indications for use Summary and explanation of the test Important considerations Other warnings, precautions, and limitations For healthcare professionals Should you speak to a genetic counselor? Test performance User studies Clinical performance For in-vitro diagnostic use Indications for Use: The 23andMe Personal Genome Service (PGS) uses qualitative genotyping to detect select clinically relevant variants in genomic DNA isolated from human saliva collected from individuals 18 years with the Oragene Dx model OGD for the purpose of reporting and interpreting genetic health risks, including the 23andMe PGS Genetic Health Risk Report for /BRCA2 (Selected Variants). The 23andMe PGS Genetic Health Risk Report for /BRCA2 (Selected Variants) is indicated for reporting of the 185delAG and 5382insC variants in the gene and the 6174delT variant in the BRCA2 gene. The report describes if a woman is at increased risk of developing breast and ovarian cancer, and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer. The three variants included in this report are most common in people of Ashkenazi Jewish descent and do not represent the majority of the /BRCA2 variants in the general population. The test report does not describe a person s overall risk of developing any type of cancer, and the absence of a variant tested does not rule out the presence of other variants that may be cancer-related. This test is not a substitute for visits to a healthcare provider for recommended screenings or appropriate follow-up and should not be used to determine any treatments. Summary and explanation of the test: 23andMe Genetic Health Risk Tests are tests you can order and use at home to learn about your DNA from a saliva sample (collected with Oragene Dx model OGD ). The tests Page 1
2 work by detecting specific gene variants using a customized multiplex assay, reagents, and instrumentation. The probability that the laboratory cannot process a sample can be up to 7.6%. Your genetic results are returned to you in a secure online account on the 23andMe website. View Frequently Asked Questions about this report here. Important: This test does not diagnose cancer or any other health conditions and should not be used on its own to make medical decisions. Results should be confirmed in a clinical setting before taking any medical action. Please follow the instructions in the DNA Collection Kit to ensure your DNA results can be processed and connected to your online account. Your ethnicity may affect whether these tests are relevant for you. Other factors, such as environmental and lifestyle risk factors, may affect the risk of developing a given disease. This test does not account for non-genetic factors, and does not test for variants in other genes linked to hereditary cancers. If you have a family history of a condition, or think you have symptoms of a condition, consult with your healthcare provider about appropriate testing. This test cannot determine your overall risk for developing a disease in the future. This device is not intended for prenatal testing. This test is not for assessing the presence of genetic variants that may impact the metabolism, exposure, response, risk of adverse events, dosing, or mechanisms of prescription or over-the-counter medications. This test is not intended to detect the presence of deterministic variants in autosomal dominant diseases or conditions. The laboratory may not be able to process your sample. If this happens, we will notify you by and you may request one free replacement kit to provide us with a new sample. Other Warnings, Precautions, and Limitations: This test includes three variants that are most common in people of Ashkenazi Jewish descent. This test does not test for all possible variants in the and BRCA2 genes. More than 1,000 variants in the and BRCA2 genes are known to increase cancer risk. The absence of a variant tested does not rule out the presence of other genetic variants that may be related to these health conditions. If you receive a zero variants detected result you should not over interpret it. You could have another variant not included in this test that may impact your cancer risk. This test is intended to be used to identify genetic risk for health conditions in users 18 years and above. This test is intended to provide you with genetic information to inform conversations with your doctor or other healthcare professional. This test is not a substitute for visits to a healthcare professional for recommended screenings, and should not be used to determine any treatments or medical interventions. You should consult with a healthcare professional if you have any questions or concerns about your results or your current state of health. Page 2
3 This test may not be able to determine a result for all variants analyzed. Different companies offering a genetic risk test may be measuring different genetic variants for the same condition, so you may get different results from a different test. Some people feel a little anxious about getting genetic health risk results. This is normal. If you feel very anxious, you should speak to your doctor or a genetic counselor prior to collecting your sample for testing. You may also consider getting your test done by your doctor. As with every test the possibility for an incorrect result exists. Speak to your personal healthcare professional or a genetic counselor if your results are unexpected. For healthcare professionals This test is not intended to diagnose a disease, determine medical treatment or other medical intervention, or tell the user anything about their current state of health. This test is intended to provide users with their genetic information, which may inform health-related lifestyle decisions and conversations with their doctor or other healthcare professional. Any diagnostic or treatment decisions must be based on confirmatory prescription testing and/or other information that you determine to be appropriate for your patient, such as additional clinical testing and other risk factors that may affect individual risk and health care. Should you speak to a genetic counselor? We encourage you to learn more so you can decide whether testing is right for you. A genetic counselor, a healthcare professional with special training in genetic conditions, will be able to answer your specific questions and help you make an informed decision. Talk to your healthcare provider or, to search for a genetic counselor near you, go to the following link (this link takes you to a page managed by the National Society of Genetic Counselors: Test performance The performance of the /BRCA2 (Selected Variants) test was assessed only for the detection of the specific gene variants analyzed by the /BRCA2 (Selected Variants) test in adults. Samples were collected using the Oragene Dx saliva collection device (OGD ). The samples were tested on the Illumina Infinium BeadChip. Results were analyzed using the Illumina iscan System and GenomeStudio and Coregen software. Analytical performance Accuracy 23andMe performed a method comparison study to assess the accuracy of the assay. Results Page 3
4 of the test were compared with sequencing results for 71 samples with known 185delAG variant status, 49 samples with known 5382insC status, and 47 samples with known 6174delT variant status. Pre-defined acceptance criteria were set to a minimum of 99% Positive Percent Agreement (PPA) and 99% Negative Percent Agreement (NPA). The method comparison study yielded >99% overall agreement for all genotypes for all samples tested, passing the predefined acceptance criteria of at least 99% PPA and 99% NPA. The 95% confidence interval was 83.9% to 100%. Genotype BeadChip Calls % PPA % NPA 95% CI Correct Incorrect No Call FQC 1 185delAG Homozygous common 185delAG Heterozygous 5382insC Homozygous common 5382insC Heterozygous BRCA2 6174delT Homozygous common BRCA2 6174delT Heterozygous Precision/Reproducibility Precision studies were performed to understand the consistency of sample measurements when tested under different conditions. Human samples of known variant status were tested for precision. Testing was performed at 2 lab sites over 3 non-consecutive days with multiple operator teams. The testing used 3 lots of reagents and 3 sets of instruments at each lab site. A total of delAG replicates from 2 unique samples, insC replicates from 2 unique samples, and delT replicates from 2 unique samples were tested. Any sample replicates failing quality control acceptance criteria were re-tested per lab procedures. Only sample replicates that passed quality control and produced a genotype for the 23andMe test 1 FQC denotes a sample or replicate which failed a quality check and was not analyzed in the study. Page 4
5 were included in the calculation for percent agreement. The precision study yielded greater than 99% correct genotype calls for all samples across multiple days, operator teams, instruments, and reagent lots at 2 independent laboratory sites. The study passed the pre-defined acceptance criteria of at least 99% correct calls. In addition, the study had greater than 99% reproducibility and greater than 99% repeatability. Minimum DNA Input A minimum DNA input study was performed to understand the lowest concentration of DNA needed for at least 95% concordant test results. This study was performed using 6 human cell line samples which were diluted to 3 concentrations (5, 15, and 50ng/µL), using 3 lots of reagents. The study yielded 100% concordant test results for all samples at all DNA concentrations tested passing all predefined acceptance criteria. The DNA input required for testing is set at a minimum of 15ng/µL and maximum of 50ng/µL DNA. Interfering Substances Studies were performed to determine whether substances that may be present in saliva affect results of the PGS tests. Four proteins that may be found in human saliva were added to saliva samples. These proteins did not affect test performance. Studies were also performed to determine whether foreign substances found in saliva affect results of the PGS tests. Saliva samples were collected from five people at three time points. First, a sample was collected before consuming a substance. Then, a sample was collected immediately after consumption. Finally, a sample was collected thirty minutes after consumption. The following conditions were tested: Eating food containing beef Eating food other than beef Drinking Chewing gum Using mouthwash Smoking The studies indicated that saliva samples should be collected at least thirty (30) minutes after eating, drinking, chewing gum, using mouthwash, or smoking. Another study was performed to assess the effects of five microbes that may be found in human saliva. The microbial DNA had no effect on the accuracy of the PGS tests. Interfering Mutations It is possible that the presence of the following variants in a sample may interfere with the performance of this test. 185delAG: rs , rs , rs , rs , rs Page 5
6 5382insC: rs , rs delT: rs , rs , rs , rs The effects of these variants on the performance of this test have not been studied. User studies Saliva collection kit user study User studies were performed to assess how well people understand the saliva collection kit instructions and to assess the ability of lay users to provide samples adequate for testing. Study participants represented a wide range of demographic characteristics. Participants were asked to collect and mail a saliva sample and answer an online survey about the collection kit instructions from home. Saliva samples were processed according to standard laboratory procedures. The overall comprehension rate on the collection kit instructions was 92.1% and greater than 97% of samples met all laboratory quality criteria, demonstrating that users from diverse backgrounds can understand the collection kit instructions and provide adequate saliva samples. PGS test report user comprehension study The key report message concepts for the /BRCA2 (Selected Variants) test were reviewed and determined to be the same as those previously tested in the device label comprehension study for the PGS Genetic Health Risk Test Reports (DEN160026). User comprehension studies were performed to assess how well people understand the PGS Genetic Health Risk Test Reports. This study was performed using test reports that are representative of Genetic Health Risk reports in general. The user comprehension study was performed in a sample that was demographically diverse, using quota-based sampling in a controlled laboratory-based environment. In addition to quantitative assessment of user comprehension of the test reports after viewing the educational module, the study was moderated face-to-face in order to collect observational and qualitative data on participants overall experience with the survey. All pre-defined demographic quotas and enrollment targets were met within the expected study duration for the overall study. Comprehension was tested through a two-step process. First, participants' understanding of genetics was tested prior to viewing the educational module and test reports. Second, participants were shown the educational module and the test reports. Participants then completed the test report comprehension survey. Overall comprehension rates per test report concept were greater than 90% across all concepts. The results of the user comprehension study are presented in DEN Clinical performance The variants covered by this test are mainly found in people of Ashkenazi Jewish descent. Published studies estimate that 1.05% of people of Ashkenazi Jewish descent carry one copy of the 185delAG variant, 0.11% carry one copy of the 5382insC variant, and 1.36% of Page 6
7 people carry one copy of the 6174delT variant. Frequency of and BRCA2 variants in 23andMe customers Variant name European African American Ashkenazi Jewish East Asian Hispanic or Latino South Asian 185delAG 0.03% <0.02% 0.89% 0.00% 0.04% 0.10% 5382insC 0.03% <0.02% 0.20% 0.00% 0.01% 0.00% 6174delT 0.03% <0.02% 1.03% 0.00% 0.01% 0.00% References 1. Tonin P et al. (1996). "Frequency of recurrent and BRCA2 mutations in Ashkenazi Jewish breast cancer families." Nat Med. 2(11): Data on file at 23andMe, Inc., Mountain View, CA This package insert describes the analytical performance of the 5 th version (v5) of the genotyping chip used to test a sample for the 23andMe Personal Genome Service. Manufactured by: 23andMe, Inc. 899 West Evelyn Mountain View, CA Contact us: Customer Care: customercare.23andme.com PI Part Number PN PI Revision A PI Revision Date April andMe, the 23andMe logo, and Welcome to You are trademarks or registered trademarks of 23andMe, Inc. Oragene is a registered trademark of DNA Genotek Inc andMe, Inc. Page 7
Medical Devices; Exemptions From Premarket Notification: Class II Devices
This document is scheduled to be published in the Federal Register on 06/05/2018 and available online at https://federalregister.gov/d/2018-11879, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationBRACAnalysis CDx Technical Information https://myriad-library.s3.amazonaws.com/technical-specifications/bracanalysis_cdx_tech_specs.
Myriad Genetics Laboratories, Inc. 320 Wakara Way, Salt Lake City, UT 84108 Phone: 1-800-469-7423 www.myriad.com Note: Test results should be communicated to the patient in a setting that includes appropriate
More informationTEST REQUISITION, PATIENT INFORMATION, AND CONSENT HUDSONALPHA CLINICAL SERVICES LABORATORY
1. Patient Information Patient Name TEST REQUISITION, PATIENT INFORMATION, AND CONSENT HUDSONALPHA CLINICAL SERVICES LABORATORY HudsonAlpha Clinical Services Lab, LLC HUDSONALPHA CLINICAL SERVICES LABORATORY
More informationwith drmid Dx for Illumina NGS systems
Performance Characteristics BRCA MASTR Dx with drmid Dx for Illumina NGS systems Manufacturer Multiplicom N.V. Galileïlaan 18 2845 Niel Belgium Revision date: July 27, 2017 Page 1 of 8 Table of Contents
More informationPersonal Genomics Platform White Paper Last Updated November 15, Executive Summary
Executive Summary Helix is a personal genomics platform company with a simple but powerful mission: to empower every person to improve their life through DNA. Our platform includes saliva sample collection,
More informationMutation entries in SMA databases Guidelines for national curators
1 Mutation entries in SMA databases Guidelines for national curators GENERAL CONSIDERATIONS Role of the curator(s) of a national database Molecular data can be collected by many different ways. There are
More informationIllumina Diagnostics. Emily Winn-Deen, PhD Vice President, Product Development Diagnostics
Introduction ti to Illumina Diagnostics Emily Winn-Deen, PhD Vice President, Product Development Diagnostics 2010 Illumina, Inc. All rights reserved. Illumina, illuminadx, Solexa, Making Sense Out of Life,
More informationUser Bulletin. Veriti 96-Well Thermal Cycler AmpFlSTR Kit Validation. Overview
User Bulletin Veriti 96-Well Thermal Cycler AmpFlSTR Kit Validation June 2009 SUBJECT: AmpFlSTR PCR Amplification Kit validation on the Veriti 96-Well Thermal Cycler with 0.2 ml sample block format In
More informationAPPLICATION TECHNICAL INFORMATION
A-1942A APPLICATION TECHNICAL INFORMATION CEQ Series MULTIPLEX MUTATION GENOTYPING FOR HUMAN DISEASES: BREAST CANCER AND FAMILIAL MEDITERRANEAN FEVER Zhiming Jiang 1, Milhan Telatar 2,Wayne Grody 2 1 Beckman
More informationTargeted Sequencing in the NBS Laboratory
Targeted Sequencing in the NBS Laboratory Christopher Greene, PhD Newborn Screening and Molecular Biology Branch Division of Laboratory Sciences Gene Sequencing in Public Health Newborn Screening February
More informationQuality Control Report for Exome Chip Data University of Michigan April, 2015
Quality Control Report for Exome Chip Data University of Michigan April, 2015 Project: Health and Retirement Study Support: U01AG009740 NIH Institute: NIA 1. Summary and recommendations for users A total
More informationMolecular Diagnostics: Market Segmentation and Opportunities
Molecular Diagnostics: Market Segmentation and Opportunities October 2010 This market report is published by DeciBio, LLC. All rights reserved. Reproduction or redistribution of this report in any form
More informationFIRST NAME MI LAST NAME BIRTH DATE (MM/DD/YYYY) GENDER. Specify countries: Name of person previously tested and relationship:
REQUEST FOR SITE SPECIFIC ANALYSIS [APC / MYH / TP53 / MLH1 / MSH2 / MSH6] Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS
More informationIllumina Clinical Services Laboratory
Illumina Clinical Services Laboratory CLIA Certificate No.: 05D1092911 Illumina Clinical Services Laboratory TruGenome Technical Sequence Data Test Requisition Form The Illumina Clinical Services Laboratory
More informationAccessible answers. Targeted sequencing: accelerating and amplifying answers for oncology research
Accessible answers Targeted sequencing: accelerating and amplifying answers for oncology research Help advance precision medicine Accelerate results with Ion Torrent NGS Life without cancer. This is our
More informationGenomic Research: Issues to Consider. IRB Brown Bag August 28, 2014 Sharon Aufox, MS, LGC
Genomic Research: Issues to Consider IRB Brown Bag August 28, 2014 Sharon Aufox, MS, LGC Outline Key genomic terms and concepts Issues in genomic research Consent models Types of findings Returning results
More informationValidating, Verifying, and Evaluating Your Test Methods: It s NOT a Regulatory Exercise!
Validating, Verifying, and Evaluating Your Test Methods: It s NOT a Regulatory Exercise! Pat Garrett, Ph.D., DABCC Renee Howell, Ph.D., MT(ASCP) SeraCare Life Sciences, Inc. AACC Annual Meeting July 29,
More informationPresented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego
Presented by: Tess L. Crisostomo Laboratory Quality Assurance/Compliance Officer Naval Medical Center San Diego Discuss the difference between DNA Genotyping and Genome Sequencing What makes you who you
More informationREQUEST FOR RETINOBLASTOMA TESTING
REQUEST FOR RETINOBLASTOMA TESTING Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS PATIENT INFORMATION* FIRST NAME MI LAST
More informationACCEL-NGS 2S DNA LIBRARY KITS
ACCEL-NGS 2S DNA LIBRARY KITS Accel-NGS 2S DNA Library Kits produce high quality libraries with an all-inclusive, easy-to-use format. The kits contain all reagents necessary to build high complexity libraries
More informationAccutest ValuPak Immunological Fecal Occult Blood Test
INTENDED USE The Accutest ValuPak Immunological Fecal Occult Blood (IFOB) Test is a rapid chromatographic immunoassay for the qualitative detection of human occult blood in human fecal specimens. The device
More informationAmerican Society of Cytopathology Core Curriculum in Molecular Biology
American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 4 Stephanie A. Hamilton, EdD, SCT, MB(ASCP) CM MD Anderson
More informationGUIDELINE ON GENOMIC SAMPLING AND MANAGEMENT OF GENOMIC DATA E18
INTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE GUIDELINE ON GENOMIC SAMPLING AND MANAGEMENT OF GENOMIC DATA E18 Current Step
More informationGenomic solutions for complex disease
Genomic solutions for complex disease Power your with our genomic solutions Access a breadth of applications. Gain a depth of insights. To enhance their understanding of complex disease, researchers are
More informationMolecular Diagnostics. Castle Medical LLC.
Molecular Diagnostics Castle Medical LLC. What is DNA testing? Pharmacogenomics is a scientific disciple that deals with the influence of patient s genotype on drug response. Objective: to deliver the
More informationMOLECULAR TESTING: VERIFYING/VALIDATING INSTRUMENTS, REAGENTS AND ASSAYS. Richard L. Hodinka, Ph.D.
MOLECULAR TESTING: VERIFYING/VALIDATING INSTRUMENTS, REAGENTS AND ASSAYS Richard L. Hodinka, Ph.D. University of South Carolina School of Medicine Greenville Greenville Health System, Greenville, SC hodinka@greenvillemed.sc.edu
More informationCytochrome P450 Genotype Panel
DOB: Age: Gender: Visit Number (FIN): Patient Results Client: Physician: ARUP Test Code: 2013098 Collection Date: 11/29/2016 Received in lab: 11/30/2016 Completion Date: 12/07/2016 Gene Genotype Phenotype
More informationFrequently Asked Questions
Frequently Asked Questions Genetics Defined What does DNA stand for? DNA stands for deoxyribonucleic acid. This term describes the different chemical building blocks that make up the structure of DNA.
More informationLysis Buffer A Wash Solution A Elution Buffer B Mini Filter Spin Columns 50 Collection Tubes 50 Elution tubes (1.7 ml) 100 Product Insert 1
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com Urine DNA Isolation Kit (Slurry Format) Product # 48800 Product
More informationMLPA assays on the SeqStudio Genetic Analyzer
APPLICATION NOTE MLPA assays on the SeqStudio Genetic Analyzer SeqStudio Genetic Analyzer In this application note, we demonstrate that: The new Applied Biosystems SeqStudio Genetic Analyzer generates
More informationCorporate Medical Policy Genetic Testing for Fanconi Anemia
Corporate Medical Policy Genetic Testing for Fanconi Anemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_fanconi_anemia 03/2015 3/2017 3/2018 12/2017 Description
More informationGCSE (9 1) Combined Science (Biology) A (Gateway Science) J250/08 Paper 8, B4 B6 and CS7 (PAGs B1 B5) (Higher Tier)
Oxford Cambridge and RSA GCSE (9 1) Combined Science (Biology) A (Gateway Science) Paper 8, B4 B6 and CS7 (PAGs B1 B5) (Higher Tier) Year 11 Test Time allowed: 1 hour 10 minutes You must have: a ruler
More informationGenentech, Inc., its research partners, collaborators, assignees, licensees or designees. Invitation to Participate
CONSENT AND RESEARCH AUTHORIZATION TO DONATE BLOOD AND TISSUE SAMPLES FOR FUTURE RESEARCH PURPOSES YALE UNIVERSITY SCHOOL OF MEDICINE YALE-NEW HAVEN HOSPITAL 200 FR. 4 Study Title: An Open-Label, Phase
More informationGENETIC TESTING A Resource from the American College of Preventive Medicine
GENETIC TESTING A Resource from the American College of Preventive Medicine A Time Tool for Clinicians ACPM's Time Tools provide an executive summary of the most up-to-date information on delivering preventive
More informationDRAFT MEDICAL DEVICE GUIDANCE DOCUMENT
November 2015 DRAFT DRAFT MEDICAL DEVICE GUIDANCE DOCUMENT REQUIREMENTS FOR LABELLING OF MEDICAL DEVICES Medical Device Authority MINISTRY OF HEALTH MALAYSIA Contents Page Preface... iii 1 Introduction.
More informationUNDERSTANDING GENETIC RESEARCH AND ALTERNATING HEMIPLEGIA OF CHILDHOOD. IT ALL BEGINS WITH THE AHC PATIENT And The Scientific Process
IT ALL BEGINS WITH THE AHC PATIENT And The Scientific Process Genetic discovery AHC Patients Need Help! Researchers collect data on AHC patients (observation) Researchers interpret and evaluate data AHC
More informationSNP GENOTYPING WITH iplex REAGENTS AND THE MASSARRAY SYSTEM
SNP GENOTYPING Accurate, sensitive, flexible MassARRAY System SNP GENOTYPING WITH iplex REAGENTS AND THE MASSARRAY SYSTEM Biomarker validation Routine genetic testing Somatic mutation profiling Up to 400
More informationUrine DNA Isolation Maxi Kit (Slurry Format) Product # 50100
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com Urine DNA Isolation Maxi Kit (Slurry Format) Product # 50100 Product
More informationTerminology: chromosome; gene; allele; proteins; enzymes
Title Workshop on genetic disease and gene therapy Authors Danielle Higham (BSc Genetics), Dr. Maggy Fostier Contact Maggy.fostier@manchester.ac.uk Target level KS4 science, GCSE (or A-level) Publication
More informationINFINITI UGT1A1 Assay Directional Package Insert (DPI)
INFINITI UGT1A1 Assay Directional Package Insert (DPI) For In Vitro Diagnostic Use FOR EXPORT ONLY Manufactured by AutoGenomics, Inc., 2980 Scott Street, Vista, CA USA 92081 Authorized EU Agent: Medical
More informationMultiplex Assay Design
Multiplex Assay Design Geeta Bhat, Luminex Molecular Diagnostics; Toronto. APHL/CDC Newborn Screening Molecular Workshop, CDC, Atlanta, GA June 28-30, 2011 Luminex Multiplexed Solutions. For Life. Luminex
More informationTaqPath ProAmp Master Mixes
PRODUCT BULLETIN es es Applied Biosystems TaqPath ProAmp Master Mixes are versatile master mixes developed for high-throughput genotyping and copy number variation (CNV) analysis protocols that require
More informationLATE-PCR. Linear-After-The-Exponential
LATE-PCR Linear-After-The-Exponential A Patented Invention of the Laboratory of Human Genetics and Reproductive Biology Lab. Director: Lawrence J. Wangh, Ph.D. Department of Biology, Brandeis University,
More informationSpinraza. Spinraza (nusinersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.15 Subject: Spinraza Page: 1 of 5 Last Review Date: June 22, 2017 Spinraza Description Spinraza (nusinersen)
More informationMRC-Holland MLPA. Description version 30;
SALSA MLPA probemix P021-A2 SMA Lot A2-0511: As compared to the previous version A1 (lots A1-0910, A1-1209, A1-0809, A1-1208, A1-0808, A1-0208 & A1-0807), two control fragments (88 and 96 nt) have been
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationMolecular Diagnostics
Molecular Diagnostics Part II: Regulations, Markets & Companies By Prof. K. K. Jain MD, FRACS, FFPM Jain PharmaBiotech Basel, Switzerland May 2018 A Jain PharmaBiotech Report A U T H O R ' S B I O G R
More informationPLTW Biomedical Science Medical Interventions Course Outline
Follow the fictitious Smith family as you learn about the prevention, diagnosis, and treatment of disease. Play the role of biomedical professionals to analyze case information and diagnose and treat your
More informationDiagnostics in Oncology Mark Kockx MD, PhD
HistoGeneX The Real World A Specialized of companion Biomarker & Integrated Pathology Laboratory Diagnostics in Oncology Mark Kockx MD, PhD 1 2 HistoGeneX located in Antwerp, Belgium and Chicago, Illinois
More informationUpdate on the IVDR. Sue Spencer
Update on the IVDR Sue Spencer Caution The new regulations are draft the principles have now been agreed but the Annexes are subject to minor changes Further details will be added later pre and post application
More informationMOLECULAR GENETICS REPORT: Glycogen Storage Disease NextGen Sequencing Panel
Patient LAST, First ID#: DOB: Sex: CLIA #: 52D2065132 CAP #: 7185561 3800 S. Business Park Ave. Marshfield, WI 54449 Sample Information Type: Collected: Received: PG ID: Ordering Provider(s) MOLECULAR
More informationtherascreen BRCA1/2 NGS FFPE gdna Kit Handbook Part 2: Analysis
February 2017 therascreen BRCA1/2 NGS FFPE gdna Kit Handbook Part 2: Analysis Version 1 For the identification of variants in BRCA1 and BRCA2 For in vitro diagnostic use For use with Illumina MiSeqDx platform
More informationREQUEST FOR HEMOPHILIA B (FACTOR IX DEFICIENCY)
REQUEST FOR HEMOPHILIA B (FACTOR IX DEFICIENCY) Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS PATIENT INFORMATION* FIRST
More informationPDGFRB FISH PRODUCT DATASHEET. Proprietary Name: PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
PDGFRB FISH PRODUCT DATASHEET Proprietary Name: PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) Established Name: PDGFRB FISH for Gleevec in MDS/MPD
More informationGenetics 101. Prepared by: James J. Messina, Ph.D., CCMHC, NCC, DCMHS Assistant Professor, Troy University, Tampa Bay Site
Genetics 101 Prepared by: James J. Messina, Ph.D., CCMHC, NCC, DCMHS Assistant Professor, Troy University, Tampa Bay Site Before we get started! Genetics 101 Additional Resources http://www.genetichealth.com/
More informationA pathogenic mutation was identified in the LDLR gene.
Hereditary High Cholesterol Test ORDERING PHYSICIAN Dr. Jenny Jones Sample Medical Group 123 Main St. Sample, CA SPECIMEN Type: Saliva Barcode: 333 234234 2343 Collected: Jul 15, 2017 Received: Jul 17,
More informationIntegrating Genomics in Family Medicine
Lehigh Valley Health Network LVHN Scholarly Works Department of Family Medicine Integrating Genomics in Family Medicine Brian Stello MD Lehigh Valley Health Network, Brian.Stello@lvhn.org Follow this and
More informationPCR SYSTEMS. a new era in high-productivity qpcr. Applied Biosystems ViiA 7 Real-Time PCR System
PCR SYSTEMS a new era in high-productivity qpcr Applied Biosystems ViiA 7 Real-Time PCR System a new era in high-productivity qpcr The ViiA 7 Real-Time PCR System delivers the proven reliability, sensitivity,
More informationGenetic testing of Tay-Sachs disease by PCR and Restriction Digest
Genetic testing of Tay-Sachs disease by PCR and Restriction Digest ESC102-PRA0103 Submitted to: Elizabeth Berndl 18 February, 2009 Submitted by: Laila Hulbert (996625077) Maria Yancheva (996742173) Scientific
More informationIntroduction to Pharmacogenetics Competency
Introduction to Pharmacogenetics Competency Updated on 6/2015 Pre-test Question # 1 Pharmacogenetics is the study of how genetic variations affect drug response a) True b) False Pre-test Question # 2 Pharmacogenetic
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.30.03.2017/06 Title: Creating a genomic medicine service to lay the foundations to deliver personalised interventions and treatments Lead Director: Professor Sir Bruce
More informationQuantStudio Dx Real-Time PCR Instrument
QuantStudio Dx Real-Time PCR Instrument Behind every diagnosis, there is a promise You believe in molecular medicine. So do we. We are committed to providing you with comprehensive solutions that help
More informationMolecular Diagnostic Assay Validation Association for Molecular Pathology Clinical Practice Committee, October 2009
Molecular Diagnostic Assay Validation Association for Molecular Pathology Clinical Practice Committee, October 2009 INTRODUCTION The primary goal of method validation in the molecular diagnostics laboratory
More informationHigh-throughput scale. Desktop simplicity.
High-throughput scale. Desktop simplicity. NextSeq 500 System. Flexible power. Speed and simplicity for whole-genome, exome, and transcriptome sequencing. Harness the power of next-generation sequencing.
More informationBiomarker Regulation. Regulator s perspective. Jan Müller-Berghaus
www.pei.de Biomarker Regulation Regulator s perspective Jan Müller-Berghaus The views presented here are my own and do not necessarily reflect the views of the Paul-Ehrlich-Institut or any other regulatory
More informationData Sources and Biobanks in the Asia-Pacific Region. Wei Zhou, MD, Ph.D. Department of Epidemiology, Merck Research Laboratories October 23, 2014
Data Sources and Biobanks in the Asia-Pacific Region Wei Zhou, MD, Ph.D. Department of Epidemiology, Merck Research Laboratories October 23, 2014 1 Disclosures Wei Zhou is currently an employee of Merck
More informationSPECIMEN INFORMATION PATIENT INFORMATION REFERRING PROVIDER INFORMATION. Institution: Same as Referring Provider
The LMM is a satellite facility of Massachusetts General Hospital. CLIA # 22D1005307 Specimen (Refer to page 4 for Specimen and Shipping requirements): SPECIMEN INFORMATION Blood (5-7mL K 2 EDTA/K 3 EDTA)
More informationVariant calling workflow for the Oncomine Comprehensive Assay using Ion Reporter Software v4.4
WHITE PAPER Oncomine Comprehensive Assay Variant calling workflow for the Oncomine Comprehensive Assay using Ion Reporter Software v4.4 Contents Scope and purpose of document...2 Content...2 How Torrent
More informationPage 1. AMPTask Force on MLS Molecular Pathology Curriculum Dear Molecular Diagnostics Laboratory Manager,
AMPTask Force on MLS Molecular Pathology Curriculum Dear Molecular Diagnostics Laboratory Manager, Recently the Association for Molecular Pathology (AMP) has decided to develop a suggested curriculum in
More informationA A T A C G T G A G T G A G G C C T T A A
Living in a Genomic World: Unraveling the Complexity of GWAS Studies by Rivka L. Glaser, Department of Biology, Stevenson University, Stevenson, MD Erin L. Zimmer, Department of Biology, Lewis University,
More informationSimplexa Spectral Calibration Panel
REF SC1100 Rev. B Spectral Templates for Real - Time PCR Determination of Spectral Matrix For in vitro Diagnostic Use INTENDED USE The Focus Diagnostics Simplexa Spectral Calibration Panel is intended
More informationTest Method Validation of In-Vitro Diagnostic Products. Tim Carr QA Manager, Beckman Coulter
Test Method Validation of In-Vitro Diagnostic Products Tim Carr QA Manager, Beckman Coulter IVD Overview What is an In-Vitro Diagnostic Test IVDs are medical devices and accessories Used to perform tests
More informationThe Agilent Technologies SureSelect Platform for Target Enrichment
The Agilent Technologies SureSelect Platform for Target Enrichment Focus your next-gen sequencing on DNA that matters Kimberly Troutman Field Applications Scientist January 27 th, 2011 Agenda 1 Introduction:
More informationA Risk-based Approach for In Vitro Companion Diagnostics Device FDA Approval Process Associated with Therapies that have Breakthrough Designation
A Risk-based Approach for In Vitro Companion Diagnostics Device FDA Approval Process Associated with Therapies that have Breakthrough Designation A Risk-based Approach for In Vitro Companion Diagnostics
More informationEVALUATION OF THEPRECISIONID SYSTEM FOR TARGETED SEQUENCING OF DNA AND RNA MARKERS FOR HUMAN IDENTITY AND BODY FLUID IDENTIFICATION
EVALUATION OF THEPRECISIONID SYSTEM FOR TARGETED SEQUENCING OF DNA AND RNA MARKERS FOR HUMAN IDENTITY AND BODY FLUID IDENTIFICATION www. tourisminbarcelona.com Jack Ballantyne HIDS, Barcelona, Spain 2016
More informationTuesday 17 May 2016 Afternoon
Oxford Cambridge and RSA H Tuesday 17 May 2016 Afternoon GCSE TWENTY FIRST CENTURY SCIENCE BIOLOGY A/SCIENCE A A161/02 Modules B1 B2 B3 (Higher Tier) *5955871405* Candidates answer on the Question Paper.
More informationGENOMICS WORKFLOW SOLUTIONS THAT GO WHERE THE SCIENCE LEADS. Genomics Solutions Portfolio
GENOMICS WORKFLOW SOLUTIONS THAT GO WHERE THE SCIENCE LEADS Genomics Solutions Portfolio WORKFLOW SOLUTIONS FROM EXTRACTION TO ANALYSIS Application-based answers for every step of your workflow Scientists
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationINFINITI System Assay for Factor II & Factor V Directional Package Insert (DPI)
INFINITI System Assay for Factor II & Factor V Directional Package Insert (DPI) For In Vitro Diagnostic Use Manufactured by AutoGenomics, Inc., 2251 Rutherford Road, Carlsbad CA USA 92008 Doc EM-34003
More informationFIRST NAME MI LAST NAME BIRTH DATE (MM/DD/YYYY) GENDER. P70.4 Neonatal hypoglycemia Q79.59 Omphalocele P08.1 Large for gestational age
REQUEST FOR BECKWITH-WIEDEMANN SYNDROME (BWS) TESTING Please provide the following information. We cannot perform your test without ALL of this information. PLEASE PRINT ALL ANSWERS PATIENT INFORMATION*
More informationMutations : D: a permanent change made to one section of DNA
Mutations : distinguish between somatic and germ mutations explain the different types of mutations explain how jumping genes influence diversity identify diseases caused by chromosomal mutations (Downs,
More informationProduct selection guide Ion GeneStudio S5 Series
Cancer genomics research Molecular profiling Ion AmpliSeq Comprehensive Cancer Panel Cat. No. 4477685 Ion AmpliSeq Made-to-Order Panels (Customize your own or browse redesigned community panels at ampliseq.com)
More informationLightScanner Hi-Res Melting Comparison of Six Master Mixes for Scanning and Small Amplicon and LunaProbes Genotyping
LightScanner Hi-Res Melting Comparison of Six Master Mixes for Scanning and Small Amplicon and LunaProbes Genotyping Introduction Commercial master mixes are convenient and cost-effective solutions for
More informationCultural competency. Training for health care providers. Last updated: December 2015
Anthem Blue Cross and Blue Shield Healthcare Solutions Medicaid Managed Care Cultural competency Training for health care providers Last updated: December 2015 What is cultural competency? Cultural competency
More informationA*01:02, 68:02 B*15:10, 58:02 DRB1*03:01, 12:01
lifetechnologies.com For In Vitro Diagnostic Use. The 3500 Dx and 3500xL Dx Genetic Analyzers CS2 and system accessories meet the requirements for IVD instrumentation in the United States. 2013 Life Technologies
More information3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: (905) Fax: (905)
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 (905) 227-8848 Fax: (905) 227-1061 Email: techsupport@norgenbiotek.com E.coli O157:H7 End-Point PCR Kit Product# EP41300 Product Insert
More informationProduct selection guide Ion S5 and Ion S5 XL Systems
Product selection guide Ion S5 and s Cancer genomics research Molecular profiling Ion AmpliSeq Ready-to-Use Panels Ion AmpliSeq Comprehensive Cancer Panel Cat. No. 4477685 Ion AmpliSeq Made-to-Order Panels
More informationGetting high-quality cytogenetic data is a SNP.
Getting high-quality cytogenetic data is a SNP. SNP data. Increased insight. Cytogenetics is at the forefront of the study of cancer and congenital disorders. And we put you at the forefront of cytogenetics.
More informationLaboratory protocol for manual purification of DNA from whole sample
Laboratory protocol for manual purification of DNA from whole sample Ethanol precipitation protocol and prepit L2P reagent for the purification of genomic DNA from the Oragene and ORAcollect families of
More informationINFINITI FMF Assay Directional Package Insert (DPI)
INFINITI FMF Assay Directional Package Insert (DPI) For In Vitro Diagnostic Use FOR EXPORT ONLY Manufactured by AutoGenomics, Inc., 2980 Scott Street, Vista, CA USA 92081 Authorized EU Agent: Medical Device
More information2017 Precision Medicine Study
2017 Precision Medicine Study www.himssanalytics.com Enabling better health through information technology. Precision Medicine Study Introduction DNA genetic testing companies such as Ancestry.com and
More informationReflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development
1 2 3 24 June 2010 EMA/CHMP/641298/2008 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug
More informationSAMPLE PROCEDURE , 11/07
SAMPLE PROCEDURE This Sample Procedure is not intended as a substitute for your facility s Procedure Manual or reagent labeling, but rather as a model for your use in customizing for your laboratory s
More informationDNA analysis. Anja Bye Post doktor. K.G. Jebsen Senter for Hjertetrening. Institutt for Sirkulasjon og Bildediagnostikk Det Medisinske Fakultet NTNU
DNA analysis Anja Bye Post doktor K.G. Jebsen Senter for Hjertetrening Institutt for Sirkulasjon og Bildediagnostikk Det Medisinske Fakultet NTNU Focus of this lecture What is DNA? Comparing DNA from different
More informationRevolutionizing genetics in the cattle industry. Extensive toolset. Proven technology. Collaborative approach.
Revolutionizing genetics in the cattle industry. Extensive toolset. Proven technology. Collaborative approach. Breed success. Join the revolution. Beef cattle with improved meat quality. Exceptional tenderness.
More informationDUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM
DUCHENNE MUSCULAR DYSTROPHY CLINICAL DEVELOPMENT PROGRAM Dana R. Martin, PharmD Sarepta Therapeutics PPMD ANNUAL CONNECT CONFERENCE ORLANDO, FLORIDA JUNE 27, 2016 FORWARD LOOKING STATEMENTS This presentation,
More informationELISA. MODULE 4 Objective 4.2 Lesson B
MODULE 4 Objective 4.2 Lesson B ELISA Course Advanced Biotechnology Unit Biotechnology Basics Essential Question How is biotechnolog y being used to advance medical diagnostics? TEKS 130.364 1A-K, 2H,
More informationMolecular Markers CRITFC Genetics Workshop December 9, 2014
Molecular Markers CRITFC Genetics Workshop December 9, 2014 Molecular Markers Tools that allow us to collect information about an individual, a population, or a species Application in fisheries mating
More information